Buy or Sell a MAT or Outpatient SUD Clinic

MAT is not one category — and buyers price it that way

Medication-assisted treatment spans a wide range of models, from federally structured opioid treatment programs to office-based practices where a prescriber delivers medication management alongside counseling. The regulatory weight, the revenue model, and the buyer pool differ materially between them — and a deal that looks comparable on revenue can be worth very different amounts.

What buyers work through:

• Which regulatory bucket the clinic sits in. Opioid treatment programs carry federal certification requirements that office-based practices do not. That structure affects transferability, compliance exposure, and who can buy it.
• Prescriber dependency. If the census follows one physician or nurse practitioner, that is the valuation risk — and it is the first thing a sophisticated buyer probes.
• Payer mix. Medicaid-heavy revenue is common in this segment and can be stable and valuable, but rate changes and state program rules are diligenced closely.
• Census quality. Retention, average length of engagement, and whether patients are stable in the program or cycling through.
• Compliance and documentation. Dosing records, counseling requirements, and documentation practices that a regulator or a buyer's diligence team will sample.
• Physical footprint. Whether the clinic is a leased storefront or an owned facility, and what the occupancy cost does to adjusted EBITDA.

Outpatient SUD alongside MAT

Many clinics operate MAT alongside IOP, outpatient counseling, and other services. That breadth is generally a strength — diversified revenue and multiple referral channels — but it also means the levels of care need to be clearly licensed, staffed, and documented. Where they are not, buyers find the gap during diligence. See our notes on PHP and IOP programs if you operate those levels of care.

What we do

On the sell side, we position the clinic around regulatory standing, prescriber depth, and payer mix, then run a controlled process with buyers who understand the segment. On the buy side, we source MAT and outpatient SUD clinics that are not publicly listed and screen for certification status, prescriber concentration, and compliance exposure before you commit.